ClinicalTrials.gov
ClinicalTrials.gov Menu

Whole-body MRI for the Detection of Metastasis (WBMRI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02183597
Recruitment Status : Withdrawn
First Posted : July 8, 2014
Last Update Posted : August 10, 2016
Sponsor:
Information provided by (Responsible Party):
Norwegian University of Science and Technology

Brief Summary:
Develop and optimize protocols for whole body MRI for detection of metastases. Evaluate diagnostic accuracy through application of optimized protocols for screening of cancer patients.

Condition or disease
Breast Cancer Metastases

Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Whole-body MRI for the Detection of Metastasis
Study Start Date : March 2016
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : March 2018

Resource links provided by the National Library of Medicine


Group/Cohort
Advanced breast cancer
Women with advanced breast cancer



Primary Outcome Measures :
  1. Number of metastasis in skeleton [ Time Frame: Baseline and after 6 months ]
    Number of skeleton metastasis will be assessed at the regular clinical follow-up of breast cancer patients with metastatic disease



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women in Mid Norway living with advanced breast cancer
Criteria

Inclusion Criteria:

- Cancer patient

Exclusion Criteria:

  • Poor general condition
  • Pacemaker or other MRI contraindications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02183597


Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Principal Investigator: Beathe Sitter, PhD Norwegian University of Science and Technology

Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT02183597     History of Changes
Other Study ID Numbers: STUC-2013-WBMRI-Sitter
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: August 10, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Norwegian University of Science and Technology:
Magnetic Resonance Imaging
Data Accuracy
Reproducibility of Results
Diagnosis

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes